Evidence from multiple tumor types suggests that TLS-derived plasma cells can produce IgG targeting tumor-associated antigens, such as MUC1 and mesothelin, and these antibodies may mediate antitumor effects through antibody-dependent cellular cytotoxicity, complement activation, or by facilitating antigen presentation [43]. The gene discussed is MSLN; the disease is neoplasm.